When to INDuce for OverWeight? (WINDOW) (WINDOW)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04603859 |
Recruitment Status :
Recruiting
First Posted : October 27, 2020
Last Update Posted : May 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pregnancy Obesity Parturition | Procedure: Elective induction of labor at 39 gestational weeks and 0 to 3 days | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1900 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | When to INDuce for OverWeight? - a Randomised Controlled Trial (WINDOW) |
Actual Study Start Date : | October 19, 2020 |
Estimated Primary Completion Date : | June 2024 |
Estimated Study Completion Date : | June 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Elective induction of labour
Elective induction of labour at 39 gestational weeks and 0 to 3 days.
|
Procedure: Elective induction of labor at 39 gestational weeks and 0 to 3 days
Elective induction of labor (eIOL) according to local policies
Other Name: eIOL |
No Intervention: Expectant management
Awaiting spontaneous labor.
|
- Caesarean section [ Time Frame: At delivery ]number (no.)
- Mode of delivery if not by caesarean [ Time Frame: At delivery ]
- Vaginal delivery - no.
- Vaginal assisted delivery - no.
- Mode of delivery [ Time Frame: At delivery ]
- Caesarean section - percent
- Vaginal delivery - percent
- Vaginal assisted delivery - percent
- Vaginal assisted delivery [ Time Frame: At delivery ]
- Forceps - no.
- Ventouse - no.
- Indication for caesarean section (more than one indication is possible) [ Time Frame: At delivery ]
- Labour dystocia - no.
- Fetal distress - no.
- Maternal request - no.
- Suspected macrosomia - no.
- Non-cephalic presentation - no.
- Extensive vaginal bleeding - no.
- Suspected uterine rupture - no.
- Maternal or fetal complication/condition (free text) - no.
- Other indication for caesarean section (free text) - no.
- Indication for vaginal assisted delivery (more than one is possible) [ Time Frame: At delivery ]
- Labour dystocia - no.
- Fetal distress - no.
- Maternal request - no.
- Other indication for assisted vaginal delivery (free text) - no.
- Use of epidural [ Time Frame: At delivery ]no.
- Damage to internal organs (bladder, bowel or ureters) [ Time Frame: At delivery to 30 days postpartum ]no.
- Uterine scar dehiscense or rupture [ Time Frame: At delivery ]no.
- Complications [ Time Frame: At delivery ]
- Minor shoulder dystocia defined as the need for McRobert's maneuver - no.
- Major shoulder dystocia defined as the need for procedures other than McRobert's maneuver - no.
- Clinical suspicion of abruption of the placenta leading to an intervention in labour - no.
- Cord prolapse - no.
- Maternal fever defined as temperature >38,2 / >38,0 degrees celsius with / without epidural - no.
- Perineal 3rd degree laceration - no.
- Perineal 4th degree laceration - no.
- Episiotomy - no.
- Postpartum haemorrhage [ Time Frame: 0-2 hours postpartum ]
- Blood loss >500ml - no.
- Blood loss >1000ml - no.
- Blood transfusion - no. Time Frame [0-2 days postpartum]
- Hysterectomy [ Time Frame: At delivery to 30 days postpartum ]no.
- Postpartum morbidity [ Time Frame: 0-30 days postpartum ]
- Puerperal infection treated in hospital - no.
- Other severe postpartum conditions treated in hospital (free text) - no.
- Maternal admission to Intensive Care Unit [ Time Frame: Enrollment to 30 days postpartum ]no.
- Maternal cardiopulmonary arrest [ Time Frame: Enrollment to 30 days postpartum ]no.
- Maternal death [ Time Frame: Enrollment to 30 days postpartum ]no.
- Primary neonatal composite including any of the following; [ Time Frame: Enrollment to 28 days of life ]
- Perinatal death (stillbirth and neonatal)
- The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame [within 72 hours after birth]
- Apgar score < 4 at 5 minutes
- Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia)
- Seizures
- Infection (defined as antibiotic treatment continuously for 7 days minimum)
- Meconium aspiration syndrome
- Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage)
- Intracranial or subgaleal hemorrhage
- Hypotension requiring vasopressor support
- Components of the primary neonatal composite will additionally be reported separately [ Time Frame: Enrollment to 28 days of life ]
- Perinatal death (stillbirth and neonatal) - no.
- The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame [within 72 hours after birth] - no.
- Apgar score < 4 at 5 minutes - no.
- Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) - no.
- Seizures - no.
- Infection (defined as antibiotic treatment continuously for 7 days minimum) - no.
- Meconium aspiration syndrome - no.
- Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) - no.
- Intracranial or subgaleal hemorrhage - no.
- Hypotension requiring vasopressor support - no.
- Neonatal trauma composite including any of the following; [ Time Frame: At delivery to 28 days of life ]
- Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage)
- Intracranial or subgaleal hemorrhage
- Neonatal asphyxia composite including any of the following; [ Time Frame: At delivery to 28 days of life ]
- Apgar score < 4 at 5 minutes
- Umbilical cord pH-value < 7.0 (allow missing data)
- Umbilical cord standard base excess (sBE) < -15.0 mmol/l (allow missing data)
- Seizures
- Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia)
- Apgar score at 5 minutes [ Time Frame: 5 minutes of life ]
- Apgar score <4 - no.
- Apgar score of 4-7 - no.
- Umbilical cord arterial and venous blood sample (allow missing data) [ Time Frame: 0-30 minutes of life ]
- pH-value < 7.0 - no.
- sBE < -15.0 mmol/l - no.
- Neonatal admission [ Time Frame: 0-72 hours of life ]no.
- Respiratory support during neonatal admission [ Time Frame: 0-28 days of life ]
- CPAP (y/n) - no.
- HNFC (y/n) - no.
- Oxygen supplement treatment (y/n) - no.
- Ventilator treatment (y/n) - no.
- Other treatment during neonatal admission [ Time Frame: 0-28 days of life ]
- Therapeutic hypothermia (y/n) - no.
- Vasopressor support (y/n) - no.
- Antibiotic treatment continuously for 7 days minimum (y/n) - no.
- Neonatal characteristics 1 [ Time Frame: At delivery ]
- Female sex - no.
- Birth weight > 4500 grams (y/n) - no.
- Neonatal characteristics 2 [ Time Frame: At delivery ]- Mean birth weight - grams
- Maternal experience on birth [ Time Frame: 4-6 weeks postpartum ]Childbirth Experience Questionnaire Scoring range is 1 to 4 where higher ratings reflect more positive experiences
- Maternal postnatal depression [ Time Frame: 4-6 weeks postpartum ]
- Major Depression Inventory (MDI)
- Edinburgh Postnatal Depression Score Scoring range is 1 to 4 where higher ratings reflect more positive experiences

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
• Pregnant women with pre- or early pregnancy BMI ≥ 30 kg/m2
Exclusion Criteria:
- Legal or ethical considerations: maternal age <18 years, language difficulties requiring an interpreter or translator
- Multiple pregnancy
- Previous caesarean section
- Uncertain gestational age, defined as gestational age determined by other measurements than the Crown-Rump length (CRL) Measurement
- Planned elective caesarean section at time of randomisation
- Fetal contraindications to IOL at time of randomisation: e.g. non-cephalic presentation, or other fetal conditions contraindicating vaginal delivery
- Fetal contraindications to expectant management at time of randomisation
- Maternal contraindications to IOL at time of randomisation: e.g. placenta previa/accreta, vasa previa
- Maternal contraindications to expectant management at time of randomisation: e.g. maternal medical conditions, ultrasonically diagnosed oligohydramnios (DVP< 2 cm), signs of labour including pre-labour rupture of membranes (PROM)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04603859
Contact: Lise Q Krogh, MD | 0045 51242102 | lise.qvirin.krogh@clin.au.dk |
Denmark | |
Aarhus University Hospital | Recruiting |
Aarhus, Denmark | |
Contact: Lise Q Krogh, MD | |
Herlev Hospital | Recruiting |
Herlev, Denmark | |
Contact: Lene Huusom, MD, PhD | |
Gødstrup Regional Hospital | Recruiting |
Herning, Denmark | |
Contact: Rubab Krogh, MD | |
North Zealand's Hospital | Not yet recruiting |
Hillerød, Denmark | |
Contact: Hanne B Westergaard, MD, PhD | |
Hvidovre Hospital | Recruiting |
Hvidovre, Denmark | |
Contact: Lone Krebs, MD, PhD | |
Kolding Hospital | Recruiting |
Kolding, Denmark | |
Contact: Annemette W Lykkebo, MD | |
Rigshospitalet Juliane Marie Centre | Recruiting |
København, Denmark | |
Contact: Kristina Renault, MD, DMSc | |
Nykøbing Falster Hospital | Recruiting |
Nykøbing Falster, Denmark | |
Contact: Jeannet Lauenborg, MD, PhD | |
Odense University Hospital | Recruiting |
Odense, Denmark | |
Contact: Christina Vinter, MD, PhD | |
Randers Regional Hospital | Recruiting |
Randers, Denmark | |
Contact: Pinar Bor, MD, PhD | |
Viborg Hospital | Recruiting |
Viborg, Denmark | |
Contact: Lise Clausen, MD |
Principal Investigator: | Lise Q Krogh, MD | Aarhus University Hospital | |
Study Chair: | Julie Glavind, MD, PhD | Aarhus University Hospital | |
Study Chair: | Sidsel Boie, MD, PhD | Randers Regional Hospital | |
Study Chair: | Jens Fuglsang, MD, PhD | Aarhus University Hospital | |
Study Chair: | Tine B Henriksen, MD, PhD | Aarhus University Hospital | |
Study Chair: | Jim Thornton, MD, PhD | Nottingham University | |
Study Chair: | Katja A Taastrøm, Midwife, MSc | Aarhus University Hospital | |
Study Chair: | Anne Cathrine M Kjeldsen, Midwife, MSc | Aarhus University Hospital |
Documents provided by Lise Krogh, University of Aarhus:
Responsible Party: | Lise Krogh, Principal Investigator, University of Aarhus |
ClinicalTrials.gov Identifier: | NCT04603859 |
Other Study ID Numbers: |
WINDOW |
First Posted: | October 27, 2020 Key Record Dates |
Last Update Posted: | May 2, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The final dataset will be publicly available in an anonymised form using an open data repository (i.e. CERN) or another equivalent database. All relevant trial-related documents will be shared along with the data. |
Time Frame: | Beginning three months and ending three years after the publication of the last trial results. |
Access Criteria: | Data will be available for any research purpose to all interested parties who have approval from an independent review committee. Interested parties will be able to request the data by contacting the trial sponsor. Authorship of publications emerging from the shared data will follow standard authorship guidelines and will include authors from the WINDOW study group depending on the nature of their involvement. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Induction of labor Expectant management Cesarean section |
Overweight Body Weight |